Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 189 | 2024 | 17591 | 6.970 |
Why?
|
South Africa | 140 | 2024 | 1872 | 5.510 |
Why?
|
Anti-HIV Agents | 44 | 2022 | 4576 | 4.110 |
Why?
|
HIV-1 | 86 | 2022 | 6962 | 3.890 |
Why?
|
Adenine | 22 | 2015 | 995 | 3.630 |
Why?
|
HIV Antibodies | 39 | 2022 | 1341 | 3.290 |
Why?
|
Acquired Immunodeficiency Syndrome | 20 | 2023 | 2203 | 2.900 |
Why?
|
Anti-Retroviral Agents | 25 | 2022 | 1795 | 2.830 |
Why?
|
Tuberculosis | 22 | 2021 | 2029 | 2.750 |
Why?
|
Antibodies, Neutralizing | 38 | 2024 | 2009 | 2.410 |
Why?
|
HIV Seropositivity | 14 | 2022 | 967 | 2.260 |
Why?
|
Vagina | 21 | 2022 | 849 | 2.210 |
Why?
|
Sexually Transmitted Diseases | 21 | 2023 | 668 | 2.200 |
Why?
|
AIDS-Related Opportunistic Infections | 10 | 2015 | 664 | 2.020 |
Why?
|
Anti-Infective Agents | 13 | 2017 | 984 | 1.890 |
Why?
|
AIDS Vaccines | 19 | 2022 | 900 | 1.770 |
Why?
|
Vaginosis, Bacterial | 8 | 2022 | 154 | 1.770 |
Why?
|
Antitubercular Agents | 13 | 2017 | 1397 | 1.760 |
Why?
|
Viral Load | 41 | 2022 | 3398 | 1.610 |
Why?
|
Herpes Genitalis | 5 | 2015 | 149 | 1.460 |
Why?
|
Reverse Transcriptase Inhibitors | 5 | 2018 | 622 | 1.440 |
Why?
|
Vaginitis | 5 | 2019 | 50 | 1.330 |
Why?
|
Vaginal Creams, Foams, and Jellies | 11 | 2017 | 62 | 1.320 |
Why?
|
Epidemics | 5 | 2019 | 517 | 1.280 |
Why?
|
Medication Adherence | 7 | 2015 | 2192 | 1.280 |
Why?
|
Genitalia, Female | 8 | 2021 | 146 | 1.280 |
Why?
|
Anti-Infective Agents, Local | 7 | 2016 | 247 | 1.270 |
Why?
|
Clinical Trials as Topic | 18 | 2021 | 8055 | 1.050 |
Why?
|
Antibodies, Monoclonal | 14 | 2023 | 9264 | 1.020 |
Why?
|
HIV | 13 | 2023 | 1597 | 0.980 |
Why?
|
Herpesvirus 2, Human | 4 | 2015 | 191 | 0.960 |
Why?
|
Cytokines | 21 | 2021 | 7453 | 0.930 |
Why?
|
Rural Health Services | 3 | 2017 | 394 | 0.910 |
Why?
|
CD4 Lymphocyte Count | 19 | 2022 | 2598 | 0.900 |
Why?
|
Trichomonas Vaginitis | 3 | 2018 | 33 | 0.890 |
Why?
|
Rural Population | 17 | 2015 | 2325 | 0.890 |
Why?
|
Hepatitis B virus | 4 | 2019 | 533 | 0.870 |
Why?
|
Vaccines, Inactivated | 1 | 2024 | 186 | 0.860 |
Why?
|
Public Health | 6 | 2023 | 2680 | 0.840 |
Why?
|
HIV Envelope Protein gp120 | 15 | 2020 | 925 | 0.840 |
Why?
|
Superinfection | 4 | 2018 | 62 | 0.840 |
Why?
|
Cervix Uteri | 7 | 2020 | 577 | 0.830 |
Why?
|
Gels | 10 | 2020 | 423 | 0.830 |
Why?
|
Rifampin | 4 | 2014 | 351 | 0.820 |
Why?
|
Hepatitis B | 7 | 2019 | 711 | 0.820 |
Why?
|
Humans | 287 | 2024 | 768970 | 0.820 |
Why?
|
Africa | 10 | 2021 | 726 | 0.810 |
Why?
|
Immunization, Passive | 5 | 2022 | 619 | 0.790 |
Why?
|
Naphthalenesulfonates | 3 | 2011 | 17 | 0.790 |
Why?
|
Benzoxazines | 2 | 2015 | 321 | 0.780 |
Why?
|
Pregnancy Complications, Infectious | 11 | 2022 | 2190 | 0.770 |
Why?
|
Trichomonas vaginalis | 4 | 2023 | 70 | 0.740 |
Why?
|
Sexual Behavior | 16 | 2018 | 2200 | 0.730 |
Why?
|
National Health Programs | 1 | 2024 | 442 | 0.730 |
Why?
|
Clinical Trials, Phase II as Topic | 4 | 2023 | 640 | 0.720 |
Why?
|
Female | 183 | 2024 | 397515 | 0.710 |
Why?
|
Immunization Programs | 3 | 2021 | 267 | 0.710 |
Why?
|
Administration, Intravaginal | 10 | 2019 | 149 | 0.710 |
Why?
|
Immune Evasion | 6 | 2021 | 376 | 0.690 |
Why?
|
Uterine Cervicitis | 3 | 2016 | 31 | 0.660 |
Why?
|
Sexual Partners | 6 | 2018 | 807 | 0.660 |
Why?
|
HIV Seronegativity | 3 | 2015 | 210 | 0.660 |
Why?
|
Drug Resistance, Viral | 5 | 2019 | 869 | 0.620 |
Why?
|
Antiretroviral Therapy, Highly Active | 7 | 2021 | 1903 | 0.620 |
Why?
|
CD4-Positive T-Lymphocytes | 17 | 2021 | 4413 | 0.620 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3118 | 0.610 |
Why?
|
Chemokines | 3 | 2022 | 963 | 0.600 |
Why?
|
Infectious Disease Transmission, Vertical | 8 | 2022 | 1360 | 0.600 |
Why?
|
Communicable Disease Control | 3 | 2021 | 857 | 0.600 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3241 | 0.600 |
Why?
|
Epitopes | 17 | 2022 | 2529 | 0.600 |
Why?
|
Women's Health Services | 2 | 2014 | 88 | 0.600 |
Why?
|
Quarantine | 1 | 2020 | 186 | 0.590 |
Why?
|
Antiviral Agents | 5 | 2019 | 3070 | 0.570 |
Why?
|
Abortion, Spontaneous | 2 | 2022 | 535 | 0.570 |
Why?
|
Neutralization Tests | 11 | 2022 | 739 | 0.570 |
Why?
|
Pandemics | 6 | 2024 | 8749 | 0.560 |
Why?
|
Mucous Membrane | 6 | 2021 | 659 | 0.550 |
Why?
|
RNA, Viral | 9 | 2019 | 2871 | 0.550 |
Why?
|
Disease Outbreaks | 5 | 2020 | 1761 | 0.540 |
Why?
|
Research Design | 7 | 2017 | 6214 | 0.530 |
Why?
|
Adult | 107 | 2024 | 223851 | 0.520 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 4 | 2021 | 306 | 0.510 |
Why?
|
Condoms | 10 | 2019 | 338 | 0.510 |
Why?
|
Communicable Diseases | 2 | 2023 | 873 | 0.500 |
Why?
|
Incidence | 24 | 2020 | 21547 | 0.500 |
Why?
|
Urban Health Services | 2 | 2014 | 177 | 0.500 |
Why?
|
Young Adult | 49 | 2024 | 60131 | 0.490 |
Why?
|
Family Planning Services | 3 | 2014 | 279 | 0.490 |
Why?
|
Antibiotics, Antitubercular | 3 | 2012 | 99 | 0.480 |
Why?
|
Vaginal Discharge | 3 | 2012 | 25 | 0.470 |
Why?
|
Polymers | 3 | 2011 | 1632 | 0.460 |
Why?
|
Rectum | 1 | 2019 | 900 | 0.460 |
Why?
|
Genital Diseases, Female | 2 | 2015 | 192 | 0.450 |
Why?
|
Social Medicine | 1 | 2014 | 64 | 0.450 |
Why?
|
Vaccines | 4 | 2023 | 843 | 0.450 |
Why?
|
Organic Anion Transporters | 1 | 2014 | 101 | 0.440 |
Why?
|
Isoniazid | 1 | 2015 | 288 | 0.440 |
Why?
|
Terminology as Topic | 1 | 2021 | 1541 | 0.440 |
Why?
|
Pregnancy Rate | 2 | 2022 | 655 | 0.440 |
Why?
|
Directive Counseling | 1 | 2015 | 171 | 0.430 |
Why?
|
Sickness Impact Profile | 1 | 2014 | 299 | 0.430 |
Why?
|
Virus Replication | 10 | 2021 | 2458 | 0.420 |
Why?
|
Gonorrhea | 3 | 2023 | 355 | 0.410 |
Why?
|
Immune Reconstitution Inflammatory Syndrome | 1 | 2012 | 61 | 0.400 |
Why?
|
HIV Seroprevalence | 6 | 2012 | 89 | 0.400 |
Why?
|
Pharmacogenetics | 1 | 2015 | 683 | 0.370 |
Why?
|
Clinical Trials, Phase I as Topic | 3 | 2022 | 330 | 0.370 |
Why?
|
Binding Sites, Antibody | 3 | 2017 | 340 | 0.360 |
Why?
|
Drug Administration Schedule | 8 | 2015 | 4862 | 0.360 |
Why?
|
Acrylic Resins | 1 | 2011 | 135 | 0.360 |
Why?
|
Human Rights | 1 | 2014 | 312 | 0.360 |
Why?
|
Truth Disclosure | 1 | 2015 | 433 | 0.360 |
Why?
|
Politics | 3 | 2014 | 822 | 0.360 |
Why?
|
Informed Consent | 3 | 2014 | 1010 | 0.350 |
Why?
|
HIV Envelope Protein gp41 | 5 | 2022 | 306 | 0.340 |
Why?
|
Antibodies, Viral | 9 | 2024 | 3215 | 0.340 |
Why?
|
Chlamydia Infections | 3 | 2023 | 365 | 0.340 |
Why?
|
Carrier State | 1 | 2013 | 529 | 0.330 |
Why?
|
Randomized Controlled Trials as Topic | 9 | 2023 | 10400 | 0.330 |
Why?
|
Adolescent | 47 | 2024 | 89244 | 0.320 |
Why?
|
Hepatitis B, Chronic | 1 | 2013 | 413 | 0.310 |
Why?
|
Criminal Law | 2 | 2020 | 97 | 0.310 |
Why?
|
Self Care | 1 | 2014 | 801 | 0.310 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2010 | 242 | 0.310 |
Why?
|
Vaccination | 10 | 2024 | 3438 | 0.300 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 5 | 2019 | 381 | 0.300 |
Why?
|
Urban Population | 5 | 2014 | 2046 | 0.300 |
Why?
|
Health Planning | 1 | 2009 | 233 | 0.290 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2012 | 878 | 0.290 |
Why?
|
Deoxycytidine | 1 | 2012 | 888 | 0.290 |
Why?
|
Lymphocyte Activation | 7 | 2019 | 5505 | 0.290 |
Why?
|
Disease Notification | 2 | 1999 | 95 | 0.280 |
Why?
|
Child Health Services | 4 | 1997 | 645 | 0.280 |
Why?
|
Point-of-Care Systems | 1 | 2016 | 1240 | 0.280 |
Why?
|
Immunoglobulin Fc Fragments | 2 | 2020 | 287 | 0.280 |
Why?
|
Inflammation | 6 | 2021 | 10868 | 0.280 |
Why?
|
Cohort Studies | 26 | 2022 | 41808 | 0.270 |
Why?
|
HIV Envelope Protein gp160 | 2 | 2019 | 96 | 0.270 |
Why?
|
Kaplan-Meier Estimate | 7 | 2015 | 6547 | 0.270 |
Why?
|
Socioeconomic Factors | 8 | 2015 | 7861 | 0.270 |
Why?
|
Placebos | 4 | 2017 | 1667 | 0.270 |
Why?
|
Male | 65 | 2024 | 365203 | 0.270 |
Why?
|
Contraceptive Agents, Female | 2 | 2020 | 123 | 0.270 |
Why?
|
Adaptation, Psychological | 2 | 2014 | 2666 | 0.270 |
Why?
|
Health Priorities | 1 | 2009 | 380 | 0.260 |
Why?
|
Developing Countries | 7 | 2006 | 2911 | 0.260 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 4 | 2017 | 215 | 0.260 |
Why?
|
Medicine, African Traditional | 2 | 1998 | 31 | 0.260 |
Why?
|
Drug Delivery Systems | 2 | 2014 | 2238 | 0.260 |
Why?
|
Epitope Mapping | 6 | 2019 | 300 | 0.250 |
Why?
|
Follow-Up Studies | 14 | 2019 | 39394 | 0.250 |
Why?
|
Measles | 3 | 1993 | 181 | 0.250 |
Why?
|
Reproductive Techniques, Assisted | 1 | 2010 | 504 | 0.250 |
Why?
|
Interferon-gamma | 7 | 2016 | 3163 | 0.250 |
Why?
|
Disease Progression | 13 | 2022 | 13674 | 0.250 |
Why?
|
Prevalence | 18 | 2022 | 15879 | 0.240 |
Why?
|
Delayed-Action Preparations | 2 | 2022 | 969 | 0.240 |
Why?
|
Safe Sex | 2 | 2018 | 144 | 0.240 |
Why?
|
Polysaccharides | 3 | 2017 | 1024 | 0.240 |
Why?
|
Seychelles | 1 | 2024 | 5 | 0.240 |
Why?
|
Polymorphism, Genetic | 2 | 2014 | 4251 | 0.230 |
Why?
|
Social Stigma | 1 | 2011 | 788 | 0.230 |
Why?
|
Pregnancy | 22 | 2022 | 30265 | 0.230 |
Why?
|
Bacteria | 3 | 2021 | 2216 | 0.230 |
Why?
|
Vaginal Douching | 2 | 2015 | 17 | 0.230 |
Why?
|
Disease Susceptibility | 6 | 2018 | 1794 | 0.230 |
Why?
|
Treatment Failure | 2 | 2022 | 2664 | 0.220 |
Why?
|
Coitus | 2 | 2014 | 133 | 0.220 |
Why?
|
Biomedical Research | 3 | 2023 | 3463 | 0.220 |
Why?
|
Toll-Like Receptors | 3 | 2020 | 582 | 0.220 |
Why?
|
Laboratory Infection | 1 | 2023 | 7 | 0.220 |
Why?
|
Prospective Studies | 18 | 2022 | 54962 | 0.220 |
Why?
|
Hepatitis A | 2 | 1994 | 126 | 0.220 |
Why?
|
Tuberculosis, Multidrug-Resistant | 3 | 2014 | 944 | 0.220 |
Why?
|
Counseling | 6 | 2020 | 1554 | 0.220 |
Why?
|
Immunity, Mucosal | 3 | 2017 | 498 | 0.210 |
Why?
|
United Nations | 2 | 2018 | 151 | 0.210 |
Why?
|
HLA-B Antigens | 3 | 2018 | 328 | 0.210 |
Why?
|
Alkynes | 2 | 2015 | 327 | 0.210 |
Why?
|
Genitalia | 2 | 2022 | 114 | 0.200 |
Why?
|
Rural Health | 6 | 2007 | 302 | 0.200 |
Why?
|
Quality of Life | 2 | 2014 | 13510 | 0.200 |
Why?
|
Cross Protection | 1 | 2022 | 25 | 0.200 |
Why?
|
Treatment Outcome | 18 | 2022 | 65480 | 0.200 |
Why?
|
Cyclopropanes | 2 | 2015 | 437 | 0.200 |
Why?
|
Alanine | 2 | 2022 | 614 | 0.200 |
Why?
|
Simian Acquired Immunodeficiency Syndrome | 2 | 2017 | 545 | 0.200 |
Why?
|
Immunoglobulin G | 6 | 2020 | 4568 | 0.200 |
Why?
|
Preventive Health Services | 2 | 2016 | 570 | 0.190 |
Why?
|
Mutation | 11 | 2021 | 30266 | 0.190 |
Why?
|
Emigration and Immigration | 2 | 2003 | 407 | 0.190 |
Why?
|
Blood | 2 | 2014 | 599 | 0.190 |
Why?
|
Federal Government | 1 | 2023 | 266 | 0.190 |
Why?
|
Health Services Needs and Demand | 1 | 2009 | 1407 | 0.190 |
Why?
|
Disease Transmission, Infectious | 4 | 2021 | 560 | 0.190 |
Why?
|
Government Programs | 1 | 2023 | 278 | 0.190 |
Why?
|
Vaginal Smears | 2 | 2014 | 505 | 0.190 |
Why?
|
Public Health Practice | 1 | 2003 | 221 | 0.190 |
Why?
|
Immunologic Memory | 4 | 2018 | 1378 | 0.180 |
Why?
|
Simian immunodeficiency virus | 2 | 2017 | 814 | 0.180 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2018 | 4651 | 0.180 |
Why?
|
Age Factors | 5 | 2021 | 18435 | 0.180 |
Why?
|
Primary Health Care | 1 | 2017 | 4748 | 0.180 |
Why?
|
Drug Therapy, Combination | 7 | 2019 | 6320 | 0.180 |
Why?
|
Betamethasone | 1 | 2020 | 48 | 0.180 |
Why?
|
Antibody Specificity | 5 | 2020 | 1065 | 0.180 |
Why?
|
Middle Aged | 34 | 2024 | 223737 | 0.180 |
Why?
|
Immunization | 3 | 2024 | 1220 | 0.170 |
Why?
|
Inflammation Mediators | 2 | 2021 | 1890 | 0.170 |
Why?
|
DNA, Viral | 2 | 2019 | 2205 | 0.170 |
Why?
|
Polymerase Chain Reaction | 5 | 2020 | 6086 | 0.170 |
Why?
|
Vulnerable Populations | 3 | 2015 | 718 | 0.170 |
Why?
|
Metronidazole | 1 | 2021 | 236 | 0.170 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2023 | 794 | 0.170 |
Why?
|
Therapeutic Irrigation | 2 | 2015 | 297 | 0.160 |
Why?
|
Immunoglobulin Isotypes | 1 | 2019 | 158 | 0.160 |
Why?
|
Risk Factors | 22 | 2023 | 74976 | 0.160 |
Why?
|
Trust | 1 | 2024 | 532 | 0.160 |
Why?
|
HIV Antigens | 2 | 2017 | 328 | 0.160 |
Why?
|
Genotype | 7 | 2021 | 13048 | 0.160 |
Why?
|
Risk-Taking | 4 | 2014 | 1023 | 0.160 |
Why?
|
Immunoglobulin Class Switching | 1 | 2020 | 289 | 0.160 |
Why?
|
Control Groups | 2 | 1998 | 107 | 0.160 |
Why?
|
Phylogeny | 8 | 2019 | 2843 | 0.160 |
Why?
|
Antibodies | 2 | 2021 | 2422 | 0.160 |
Why?
|
Students | 3 | 2014 | 1744 | 0.150 |
Why?
|
Bacterial Translocation | 2 | 2021 | 74 | 0.150 |
Why?
|
Health Services Accessibility | 3 | 2014 | 5522 | 0.150 |
Why?
|
Kenya | 3 | 2020 | 758 | 0.150 |
Why?
|
Bodily Secretions | 2 | 2015 | 28 | 0.150 |
Why?
|
Gardnerella vaginalis | 1 | 2018 | 20 | 0.150 |
Why?
|
Health Resources | 3 | 2021 | 951 | 0.150 |
Why?
|
Killer Cells, Natural | 4 | 2020 | 2211 | 0.150 |
Why?
|
Toll-Like Receptor 4 | 2 | 2019 | 587 | 0.150 |
Why?
|
Double-Blind Method | 7 | 2022 | 12467 | 0.150 |
Why?
|
Cross-Sectional Studies | 13 | 2022 | 26395 | 0.140 |
Why?
|
Abortion, Incomplete | 1 | 1997 | 13 | 0.140 |
Why?
|
nef Gene Products, Human Immunodeficiency Virus | 2 | 2014 | 149 | 0.140 |
Why?
|
Plasma | 3 | 2019 | 585 | 0.140 |
Why?
|
Antibody Affinity | 2 | 2015 | 253 | 0.140 |
Why?
|
Health Knowledge, Attitudes, Practice | 6 | 2012 | 4056 | 0.140 |
Why?
|
Uncertainty | 1 | 2022 | 769 | 0.140 |
Why?
|
International Cooperation | 1 | 2023 | 1436 | 0.140 |
Why?
|
Condoms, Female | 1 | 2016 | 4 | 0.140 |
Why?
|
Epitopes, T-Lymphocyte | 3 | 2019 | 827 | 0.140 |
Why?
|
Chlamydia trachomatis | 3 | 2023 | 239 | 0.140 |
Why?
|
Lymphocytes | 2 | 2016 | 2614 | 0.140 |
Why?
|
Time Factors | 12 | 2021 | 40261 | 0.140 |
Why?
|
Semen | 2 | 2021 | 350 | 0.140 |
Why?
|
Maternal Welfare | 1 | 1997 | 113 | 0.130 |
Why?
|
Cyclophilin A | 1 | 2016 | 57 | 0.130 |
Why?
|
Ethics, Medical | 2 | 2000 | 785 | 0.130 |
Why?
|
Pregnant Women | 2 | 1998 | 576 | 0.130 |
Why?
|
Gene Products, gag | 1 | 2017 | 317 | 0.130 |
Why?
|
History, 20th Century | 2 | 2014 | 2771 | 0.130 |
Why?
|
Mobile Health Units | 1 | 1997 | 93 | 0.130 |
Why?
|
Introns | 1 | 2018 | 969 | 0.130 |
Why?
|
Food Supply | 1 | 2021 | 544 | 0.130 |
Why?
|
Systems Integration | 1 | 2017 | 430 | 0.130 |
Why?
|
Receptors, KIR | 1 | 2016 | 114 | 0.130 |
Why?
|
Neisseria gonorrhoeae | 3 | 2023 | 249 | 0.130 |
Why?
|
Hospitals, Public | 1 | 1997 | 204 | 0.130 |
Why?
|
AIDS Serodiagnosis | 2 | 2012 | 220 | 0.120 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2018 | 296 | 0.120 |
Why?
|
B-Lymphocytes | 5 | 2016 | 4794 | 0.120 |
Why?
|
Child Welfare | 2 | 2012 | 523 | 0.120 |
Why?
|
Transients and Migrants | 2 | 1997 | 170 | 0.120 |
Why?
|
Interleukin-8 | 2 | 2015 | 705 | 0.120 |
Why?
|
Case-Control Studies | 9 | 2022 | 22296 | 0.120 |
Why?
|
Epigenesis, Genetic | 2 | 2021 | 3836 | 0.120 |
Why?
|
Health Policy | 4 | 2023 | 2700 | 0.120 |
Why?
|
Epitopes, B-Lymphocyte | 2 | 2014 | 85 | 0.120 |
Why?
|
Directly Observed Therapy | 2 | 2006 | 139 | 0.120 |
Why?
|
Virus Internalization | 1 | 2018 | 503 | 0.120 |
Why?
|
Genes, Immunoglobulin | 1 | 2015 | 286 | 0.110 |
Why?
|
Drug Evaluation | 2 | 2014 | 642 | 0.110 |
Why?
|
Genes, MHC Class I | 1 | 2014 | 236 | 0.110 |
Why?
|
Maternal Health Services | 2 | 2012 | 472 | 0.110 |
Why?
|
Freedom | 1 | 2014 | 69 | 0.110 |
Why?
|
Mass Screening | 3 | 2020 | 5457 | 0.110 |
Why?
|
Disease-Free Survival | 3 | 2013 | 6856 | 0.110 |
Why?
|
Immunity, Innate | 3 | 2016 | 3080 | 0.110 |
Why?
|
Chromosomes, Human, Y | 1 | 2014 | 164 | 0.110 |
Why?
|
Body Fluids | 1 | 2015 | 322 | 0.110 |
Why?
|
Papillomaviridae | 1 | 2019 | 1140 | 0.110 |
Why?
|
Gene Expression Regulation | 5 | 2020 | 11932 | 0.110 |
Why?
|
Metabolic Clearance Rate | 2 | 2011 | 363 | 0.110 |
Why?
|
Integrins | 1 | 2018 | 843 | 0.110 |
Why?
|
Receptors, CCR5 | 1 | 2015 | 491 | 0.110 |
Why?
|
Health Services | 3 | 2012 | 755 | 0.110 |
Why?
|
Patient Rights | 1 | 2014 | 126 | 0.110 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2015 | 423 | 0.110 |
Why?
|
Community Networks | 1 | 2015 | 202 | 0.100 |
Why?
|
Contraceptive Devices, Male | 1 | 1992 | 13 | 0.100 |
Why?
|
Acute Disease | 5 | 2016 | 7245 | 0.100 |
Why?
|
Community-Based Participatory Research | 1 | 2015 | 223 | 0.100 |
Why?
|
Urine | 1 | 2014 | 362 | 0.100 |
Why?
|
Interleukin-17 | 2 | 2015 | 925 | 0.100 |
Why?
|
Chemokine CCL2 | 1 | 2015 | 606 | 0.100 |
Why?
|
Exons | 1 | 2018 | 2395 | 0.100 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2020 | 1658 | 0.100 |
Why?
|
Haplotypes | 2 | 2016 | 2725 | 0.100 |
Why?
|
Pilot Projects | 4 | 2018 | 8748 | 0.100 |
Why?
|
Cost-Benefit Analysis | 4 | 2017 | 5544 | 0.100 |
Why?
|
HIV Core Protein p24 | 1 | 2012 | 247 | 0.100 |
Why?
|
Peptide Hydrolases | 1 | 2015 | 610 | 0.100 |
Why?
|
Prenatal Care | 4 | 2004 | 1162 | 0.100 |
Why?
|
Education, Medical | 1 | 2004 | 1742 | 0.100 |
Why?
|
Feasibility Studies | 2 | 2014 | 5323 | 0.100 |
Why?
|
Macaca mulatta | 2 | 2017 | 2365 | 0.100 |
Why?
|
Alleles | 4 | 2016 | 6901 | 0.100 |
Why?
|
Patient Compliance | 4 | 2010 | 2701 | 0.100 |
Why?
|
Nevirapine | 2 | 2003 | 273 | 0.100 |
Why?
|
Receptors, Virus | 1 | 2015 | 652 | 0.100 |
Why?
|
Biotransformation | 1 | 2011 | 166 | 0.100 |
Why?
|
Hepatitis D | 1 | 1991 | 23 | 0.100 |
Why?
|
Health Status Indicators | 1 | 1997 | 971 | 0.100 |
Why?
|
Tablets | 1 | 2012 | 149 | 0.100 |
Why?
|
Substance Abuse, Intravenous | 1 | 2016 | 530 | 0.100 |
Why?
|
Administration, Topical | 2 | 2012 | 704 | 0.090 |
Why?
|
Animals | 12 | 2023 | 169335 | 0.090 |
Why?
|
Chemoprevention | 1 | 2013 | 326 | 0.090 |
Why?
|
Measles Vaccine | 1 | 1991 | 80 | 0.090 |
Why?
|
Leukocytes, Mononuclear | 4 | 2021 | 1855 | 0.090 |
Why?
|
Anti-Bacterial Agents | 4 | 2022 | 7478 | 0.090 |
Why?
|
Sputum | 1 | 2014 | 517 | 0.090 |
Why?
|
Licensure | 1 | 2012 | 127 | 0.090 |
Why?
|
Health Education | 5 | 2003 | 1059 | 0.090 |
Why?
|
Tissue Distribution | 1 | 2015 | 2298 | 0.090 |
Why?
|
Germ Cells | 1 | 2015 | 644 | 0.090 |
Why?
|
Reproductive Health Services | 1 | 2012 | 90 | 0.090 |
Why?
|
Quality Improvement | 2 | 2017 | 3860 | 0.090 |
Why?
|
Anti-Inflammatory Agents | 1 | 2020 | 1811 | 0.090 |
Why?
|
Half-Life | 1 | 2011 | 651 | 0.090 |
Why?
|
Antigens, CD | 1 | 2021 | 4032 | 0.090 |
Why?
|
Immunity, Maternally-Acquired | 1 | 1991 | 112 | 0.090 |
Why?
|
Amino Acid Sequence | 8 | 2017 | 13427 | 0.090 |
Why?
|
Host-Pathogen Interactions | 4 | 2021 | 1469 | 0.090 |
Why?
|
Patient Acceptance of Health Care | 4 | 2003 | 3235 | 0.090 |
Why?
|
Personal Satisfaction | 1 | 2014 | 645 | 0.080 |
Why?
|
Program Evaluation | 2 | 2014 | 2508 | 0.080 |
Why?
|
Sensitivity and Specificity | 4 | 2023 | 14752 | 0.080 |
Why?
|
Antibody Diversity | 1 | 2009 | 72 | 0.080 |
Why?
|
Recombination, Genetic | 1 | 2014 | 1526 | 0.080 |
Why?
|
Cell Movement | 3 | 2016 | 5216 | 0.080 |
Why?
|
False Positive Reactions | 1 | 2012 | 963 | 0.080 |
Why?
|
Immunization Schedule | 1 | 1991 | 228 | 0.080 |
Why?
|
Cytoskeletal Proteins | 1 | 2015 | 1328 | 0.080 |
Why?
|
Interleukin-10 | 1 | 2015 | 1183 | 0.080 |
Why?
|
Recurrence | 3 | 2021 | 8513 | 0.080 |
Why?
|
Longitudinal Studies | 7 | 2021 | 14794 | 0.080 |
Why?
|
Physician's Role | 1 | 1996 | 926 | 0.080 |
Why?
|
Logistic Models | 5 | 2018 | 13318 | 0.080 |
Why?
|
Th17 Cells | 1 | 2015 | 791 | 0.080 |
Why?
|
Drug Interactions | 2 | 2011 | 1418 | 0.080 |
Why?
|
DNA Methylation | 2 | 2021 | 4432 | 0.080 |
Why?
|
Integrases | 1 | 2011 | 520 | 0.080 |
Why?
|
Clinical Protocols | 1 | 2014 | 1445 | 0.080 |
Why?
|
Sample Size | 1 | 2012 | 848 | 0.080 |
Why?
|
Molecular Sequence Data | 8 | 2014 | 17629 | 0.080 |
Why?
|
Violence | 2 | 2012 | 936 | 0.080 |
Why?
|
Gene Frequency | 1 | 2015 | 3626 | 0.080 |
Why?
|
School Health Services | 1 | 2012 | 388 | 0.080 |
Why?
|
Peptide Fragments | 3 | 2018 | 5151 | 0.080 |
Why?
|
Hospitalization | 3 | 2024 | 10847 | 0.080 |
Why?
|
Disclosure | 1 | 2014 | 755 | 0.080 |
Why?
|
Research | 4 | 2018 | 1981 | 0.080 |
Why?
|
Cytomegalovirus | 1 | 2012 | 753 | 0.070 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2010 | 340 | 0.070 |
Why?
|
Cytidine Deaminase | 1 | 2010 | 249 | 0.070 |
Why?
|
Communication | 1 | 2022 | 3908 | 0.070 |
Why?
|
United States | 6 | 2023 | 73186 | 0.070 |
Why?
|
Papillomavirus Infections | 1 | 2019 | 1640 | 0.070 |
Why?
|
History, 21st Century | 1 | 2014 | 1575 | 0.070 |
Why?
|
Mutation, Missense | 1 | 2017 | 2592 | 0.070 |
Why?
|
Sequence Analysis, RNA | 3 | 2021 | 2041 | 0.070 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 5 | 2012 | 3813 | 0.070 |
Why?
|
Virulence | 2 | 2021 | 1298 | 0.070 |
Why?
|
Zambia | 2 | 2020 | 273 | 0.070 |
Why?
|
Radiography, Thoracic | 1 | 2014 | 1321 | 0.070 |
Why?
|
Proportional Hazards Models | 4 | 2018 | 12562 | 0.070 |
Why?
|
Africa South of the Sahara | 1 | 2010 | 753 | 0.070 |
Why?
|
Retrospective Studies | 7 | 2024 | 81903 | 0.070 |
Why?
|
Immunocompromised Host | 1 | 2012 | 863 | 0.070 |
Why?
|
Data Collection | 1 | 1996 | 3324 | 0.070 |
Why?
|
Intestines | 1 | 2016 | 1911 | 0.070 |
Why?
|
Infant | 10 | 2006 | 36556 | 0.070 |
Why?
|
Child, Institutionalized | 1 | 1988 | 111 | 0.070 |
Why?
|
Sequence Analysis, DNA | 2 | 2017 | 4785 | 0.070 |
Why?
|
Educational Status | 1 | 2014 | 2515 | 0.070 |
Why?
|
India | 2 | 2010 | 2334 | 0.070 |
Why?
|
Flow Cytometry | 5 | 2018 | 5906 | 0.070 |
Why?
|
Ambulatory Surgical Procedures | 1 | 1991 | 472 | 0.070 |
Why?
|
Saquinavir | 1 | 2006 | 29 | 0.070 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 2862 | 0.070 |
Why?
|
World Health Organization | 1 | 2012 | 1328 | 0.060 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2016 | 16053 | 0.060 |
Why?
|
Drug Combinations | 1 | 2012 | 2089 | 0.060 |
Why?
|
Cell Line | 5 | 2021 | 15604 | 0.060 |
Why?
|
Carrier Proteins | 2 | 2021 | 4939 | 0.060 |
Why?
|
Viremia | 2 | 2019 | 725 | 0.060 |
Why?
|
T-Lymphocytes | 2 | 2015 | 10276 | 0.060 |
Why?
|
Pyrimidines | 1 | 2018 | 3048 | 0.060 |
Why?
|
Cross Reactions | 3 | 2013 | 828 | 0.060 |
Why?
|
Health Care Costs | 2 | 2015 | 3270 | 0.060 |
Why?
|
Schools | 1 | 2014 | 1498 | 0.060 |
Why?
|
Evidence-Based Practice | 1 | 2009 | 500 | 0.060 |
Why?
|
Penicillin G Benzathine | 1 | 2004 | 25 | 0.060 |
Why?
|
Interleukin-6 | 1 | 2015 | 3232 | 0.060 |
Why?
|
Drug Approval | 1 | 2012 | 821 | 0.060 |
Why?
|
Complementarity Determining Regions | 2 | 2017 | 154 | 0.060 |
Why?
|
Needle Sharing | 1 | 2004 | 22 | 0.060 |
Why?
|
Stereotyping | 1 | 2007 | 241 | 0.060 |
Why?
|
Regression Analysis | 1 | 2014 | 6346 | 0.060 |
Why?
|
Dendritic Cells | 1 | 2016 | 2748 | 0.060 |
Why?
|
Geography | 1 | 2007 | 654 | 0.060 |
Why?
|
Social Support | 1 | 2015 | 2193 | 0.060 |
Why?
|
Quality Indicators, Health Care | 1 | 2014 | 1812 | 0.060 |
Why?
|
Breast Feeding | 2 | 2003 | 1364 | 0.060 |
Why?
|
Motivation | 1 | 2014 | 2025 | 0.060 |
Why?
|
Syringes | 1 | 2004 | 58 | 0.060 |
Why?
|
Pregnancy Outcome | 3 | 2010 | 2974 | 0.060 |
Why?
|
Africa, Southern | 1 | 2023 | 60 | 0.060 |
Why?
|
Infant, Newborn | 9 | 2004 | 26428 | 0.060 |
Why?
|
Escherichia coli | 2 | 2015 | 4213 | 0.060 |
Why?
|
Genome, Viral | 2 | 2021 | 673 | 0.060 |
Why?
|
Monocytes | 1 | 2013 | 2603 | 0.060 |
Why?
|
Ritonavir | 1 | 2006 | 332 | 0.060 |
Why?
|
Hepatitis B Surface Antigens | 3 | 1991 | 294 | 0.060 |
Why?
|
Drug Monitoring | 2 | 2020 | 965 | 0.050 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2015 | 4356 | 0.050 |
Why?
|
Cells, Cultured | 4 | 2021 | 19023 | 0.050 |
Why?
|
Blotting, Western | 1 | 2011 | 5033 | 0.050 |
Why?
|
Hepatitis Antibodies | 2 | 1993 | 67 | 0.050 |
Why?
|
HIV Protease Inhibitors | 1 | 2006 | 432 | 0.050 |
Why?
|
Drug Resistance | 1 | 2009 | 1599 | 0.050 |
Why?
|
Nucleocapsid Proteins | 1 | 2023 | 75 | 0.050 |
Why?
|
Heterosexuality | 2 | 2018 | 309 | 0.050 |
Why?
|
Sex Factors | 4 | 2010 | 10633 | 0.050 |
Why?
|
Deoxyadenosines | 1 | 2022 | 27 | 0.050 |
Why?
|
Repressor Proteins | 1 | 2014 | 2986 | 0.050 |
Why?
|
Hepatitis C | 1 | 1993 | 1595 | 0.050 |
Why?
|
Child | 13 | 2014 | 80960 | 0.050 |
Why?
|
Seroepidemiologic Studies | 2 | 2014 | 405 | 0.050 |
Why?
|
Immunoglobulin Variable Region | 2 | 2015 | 420 | 0.050 |
Why?
|
CD4-CD8 Ratio | 1 | 2022 | 114 | 0.050 |
Why?
|
Data Interpretation, Statistical | 1 | 2012 | 2714 | 0.050 |
Why?
|
Crystallography, X-Ray | 2 | 2017 | 1952 | 0.050 |
Why?
|
Cluster Analysis | 1 | 2009 | 2732 | 0.050 |
Why?
|
Syphilis | 1 | 2004 | 243 | 0.050 |
Why?
|
Child, Preschool | 10 | 1997 | 42683 | 0.050 |
Why?
|
Solvents | 1 | 2022 | 298 | 0.050 |
Why?
|
Therapeutic Human Experimentation | 2 | 1998 | 43 | 0.050 |
Why?
|
Sequence Alignment | 2 | 2017 | 2179 | 0.050 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2011 | 2911 | 0.050 |
Why?
|
Women's Health | 1 | 2010 | 2081 | 0.050 |
Why?
|
Phytohemagglutinins | 1 | 2020 | 165 | 0.050 |
Why?
|
Prisoners | 1 | 2004 | 316 | 0.050 |
Why?
|
Tuberculosis, Pulmonary | 2 | 2006 | 843 | 0.050 |
Why?
|
Risk Assessment | 4 | 2017 | 24333 | 0.050 |
Why?
|
Zimbabwe | 2 | 2015 | 135 | 0.050 |
Why?
|
Azabicyclo Compounds | 1 | 2021 | 68 | 0.040 |
Why?
|
Immunophenotyping | 2 | 2018 | 1866 | 0.040 |
Why?
|
Public Sector | 2 | 2012 | 266 | 0.040 |
Why?
|
Population Surveillance | 2 | 2009 | 2597 | 0.040 |
Why?
|
Protein Structure, Tertiary | 3 | 2014 | 3775 | 0.040 |
Why?
|
Patient Selection | 1 | 2012 | 4265 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 7460 | 0.040 |
Why?
|
Biological Assay | 1 | 2023 | 628 | 0.040 |
Why?
|
Nonoxynol | 1 | 1999 | 12 | 0.040 |
Why?
|
Leadership | 1 | 2009 | 1396 | 0.040 |
Why?
|
Spermatocidal Agents | 1 | 1999 | 15 | 0.040 |
Why?
|
Acute-Phase Proteins | 1 | 2021 | 252 | 0.040 |
Why?
|
GPI-Linked Proteins | 1 | 2021 | 472 | 0.040 |
Why?
|
Interleukin-1beta | 2 | 2015 | 1026 | 0.040 |
Why?
|
Drug Resistance, Microbial | 1 | 2002 | 830 | 0.040 |
Why?
|
Cell Differentiation | 2 | 2018 | 11684 | 0.040 |
Why?
|
Drug Packaging | 1 | 1999 | 44 | 0.040 |
Why?
|
Adenosine Monophosphate | 1 | 2021 | 232 | 0.040 |
Why?
|
Multivariate Analysis | 3 | 2018 | 12095 | 0.040 |
Why?
|
Research Subjects | 2 | 1998 | 249 | 0.040 |
Why?
|
Ibuprofen | 1 | 2020 | 229 | 0.040 |
Why?
|
Ambulatory Care | 2 | 2010 | 2784 | 0.040 |
Why?
|
Computer Simulation | 2 | 2017 | 6291 | 0.040 |
Why?
|
Virus Latency | 1 | 2021 | 360 | 0.040 |
Why?
|
Severity of Illness Index | 2 | 2012 | 15951 | 0.040 |
Why?
|
DNA Primers | 2 | 2014 | 2827 | 0.040 |
Why?
|
Endemic Diseases | 1 | 2019 | 191 | 0.040 |
Why?
|
Models, Biological | 2 | 2011 | 9499 | 0.040 |
Why?
|
Immunoglobulins | 1 | 2021 | 855 | 0.040 |
Why?
|
Social Justice | 1 | 2023 | 486 | 0.040 |
Why?
|
Prognosis | 4 | 2022 | 30046 | 0.040 |
Why?
|
Ethical Review | 1 | 1998 | 27 | 0.040 |
Why?
|
Anemia | 1 | 2008 | 1517 | 0.040 |
Why?
|
Circumcision, Male | 1 | 2019 | 148 | 0.040 |
Why?
|
HEK293 Cells | 2 | 2018 | 4290 | 0.040 |
Why?
|
Hepatitis B Antibodies | 2 | 1989 | 156 | 0.040 |
Why?
|
Reproducibility of Results | 1 | 2016 | 20245 | 0.040 |
Why?
|
Gardnerella | 1 | 2017 | 2 | 0.040 |
Why?
|
Health Status Disparities | 1 | 2009 | 1886 | 0.040 |
Why?
|
Developed Countries | 1 | 2000 | 452 | 0.040 |
Why?
|
Age Distribution | 2 | 2012 | 2875 | 0.030 |
Why?
|
Evaluation Studies as Topic | 1 | 1999 | 1629 | 0.030 |
Why?
|
Health Surveys | 2 | 2019 | 4055 | 0.030 |
Why?
|
Decision Support Techniques | 1 | 2006 | 2008 | 0.030 |
Why?
|
Cell Separation | 2 | 2012 | 1728 | 0.030 |
Why?
|
Amino Acids | 1 | 2022 | 1716 | 0.030 |
Why?
|
HIV Integrase Inhibitors | 1 | 2018 | 165 | 0.030 |
Why?
|
Poverty | 2 | 2018 | 2720 | 0.030 |
Why?
|
Amino Acid Motifs | 2 | 2009 | 930 | 0.030 |
Why?
|
Antibodies, Blocking | 1 | 2016 | 250 | 0.030 |
Why?
|
Receptors, Fc | 1 | 2019 | 538 | 0.030 |
Why?
|
Antigens, Viral | 1 | 2020 | 996 | 0.030 |
Why?
|
Oxazines | 1 | 2018 | 358 | 0.030 |
Why?
|
Chromatography, Liquid | 1 | 2020 | 997 | 0.030 |
Why?
|
Fees and Charges | 1 | 1997 | 191 | 0.030 |
Why?
|
Immunity | 1 | 2022 | 1003 | 0.030 |
Why?
|
Lactobacillus | 1 | 2017 | 212 | 0.030 |
Why?
|
Causality | 1 | 2022 | 1256 | 0.030 |
Why?
|
HLA-C Antigens | 1 | 2016 | 146 | 0.030 |
Why?
|
Resource Allocation | 1 | 1998 | 354 | 0.030 |
Why?
|
Personal Autonomy | 1 | 1998 | 315 | 0.030 |
Why?
|
State Medicine | 1 | 1997 | 219 | 0.030 |
Why?
|
Antigenic Variation | 1 | 2015 | 118 | 0.030 |
Why?
|
Sterilization, Tubal | 1 | 2015 | 78 | 0.030 |
Why?
|
Chemokine CCL20 | 1 | 2015 | 64 | 0.030 |
Why?
|
Uganda | 1 | 2020 | 1361 | 0.030 |
Why?
|
Referral and Consultation | 3 | 1997 | 3628 | 0.030 |
Why?
|
Virus Attachment | 1 | 2015 | 57 | 0.030 |
Why?
|
Confidentiality | 1 | 1999 | 606 | 0.030 |
Why?
|
Evolution, Molecular | 2 | 2014 | 1894 | 0.030 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2012 | 1803 | 0.030 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2018 | 3671 | 0.030 |
Why?
|
Comorbidity | 1 | 2009 | 10592 | 0.030 |
Why?
|
Odds Ratio | 2 | 2016 | 9684 | 0.030 |
Why?
|
Consensus Sequence | 1 | 2015 | 363 | 0.030 |
Why?
|
Chronic Disease | 3 | 2016 | 9384 | 0.030 |
Why?
|
Malawi | 1 | 2015 | 312 | 0.030 |
Why?
|
Phagocytosis | 1 | 2020 | 1530 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2018 | 1586 | 0.030 |
Why?
|
Biodiversity | 1 | 2017 | 345 | 0.030 |
Why?
|
Chemokine CXCL10 | 1 | 2015 | 311 | 0.030 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2015 | 190 | 0.030 |
Why?
|
Quinazolines | 1 | 2021 | 1373 | 0.030 |
Why?
|
Kinetics | 2 | 2012 | 6332 | 0.030 |
Why?
|
Injections, Intramuscular | 1 | 2015 | 556 | 0.030 |
Why?
|
Organ Specificity | 1 | 2019 | 1970 | 0.030 |
Why?
|
Hepatovirus | 1 | 1993 | 45 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 4592 | 0.030 |
Why?
|
Gene Products, env | 1 | 2015 | 250 | 0.030 |
Why?
|
Chromates | 1 | 1993 | 22 | 0.030 |
Why?
|
Hepatitis A Antibodies | 1 | 1993 | 19 | 0.030 |
Why?
|
Hepatitis, Viral, Human | 1 | 1994 | 141 | 0.030 |
Why?
|
Glycosylation | 1 | 2017 | 1101 | 0.030 |
Why?
|
Drug Industry | 1 | 2000 | 793 | 0.030 |
Why?
|
Somatic Hypermutation, Immunoglobulin | 1 | 2014 | 103 | 0.030 |
Why?
|
Chemical Industry | 1 | 1993 | 115 | 0.030 |
Why?
|
Social Class | 1 | 2002 | 2009 | 0.030 |
Why?
|
Tandem Mass Spectrometry | 1 | 2020 | 1197 | 0.030 |
Why?
|
Administration, Oral | 1 | 2021 | 4040 | 0.030 |
Why?
|
Papillomavirus Vaccines | 1 | 2019 | 497 | 0.030 |
Why?
|
Dexamethasone | 1 | 2021 | 1965 | 0.030 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2015 | 353 | 0.030 |
Why?
|
Nose Diseases | 1 | 1993 | 79 | 0.030 |
Why?
|
Outpatient Clinics, Hospital | 2 | 1998 | 395 | 0.030 |
Why?
|
Transforming Growth Factor beta | 1 | 2021 | 2004 | 0.030 |
Why?
|
Encephalomyelitis, Venezuelan Equine | 1 | 2012 | 1 | 0.030 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2017 | 1048 | 0.030 |
Why?
|
Candidiasis | 1 | 2015 | 367 | 0.030 |
Why?
|
Alphavirus | 1 | 2012 | 9 | 0.030 |
Why?
|
Pyridones | 1 | 2018 | 819 | 0.030 |
Why?
|
Healthy People Programs | 1 | 2012 | 54 | 0.030 |
Why?
|
Toll-Like Receptor 8 | 1 | 2013 | 98 | 0.030 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2014 | 304 | 0.030 |
Why?
|
Models, Molecular | 2 | 2014 | 5404 | 0.030 |
Why?
|
Nasal Septum | 1 | 1993 | 131 | 0.030 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2015 | 648 | 0.020 |
Why?
|
Enzyme-Linked Immunospot Assay | 1 | 2012 | 126 | 0.020 |
Why?
|
Antibody Formation | 1 | 2017 | 1393 | 0.020 |
Why?
|
Selection, Genetic | 1 | 2017 | 878 | 0.020 |
Why?
|
HIV-2 | 1 | 1992 | 156 | 0.020 |
Why?
|
Administration, Rectal | 1 | 2011 | 69 | 0.020 |
Why?
|
Avian Proteins | 1 | 2012 | 78 | 0.020 |
Why?
|
Toll-Like Receptor 7 | 1 | 2013 | 169 | 0.020 |
Why?
|
Risk | 2 | 2018 | 9621 | 0.020 |
Why?
|
Receptors, Chemokine | 1 | 2015 | 652 | 0.020 |
Why?
|
Transcription Factors | 1 | 2011 | 12174 | 0.020 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2015 | 892 | 0.020 |
Why?
|
Space-Time Clustering | 1 | 1991 | 45 | 0.020 |
Why?
|
DNA, Complementary | 1 | 2015 | 1990 | 0.020 |
Why?
|
Emergency Service, Hospital | 1 | 1991 | 7957 | 0.020 |
Why?
|
Anonymous Testing | 1 | 1991 | 10 | 0.020 |
Why?
|
Fatty Acid-Binding Proteins | 1 | 2013 | 294 | 0.020 |
Why?
|
Toll-Like Receptor 9 | 1 | 2012 | 199 | 0.020 |
Why?
|
Immunoassay | 1 | 2015 | 746 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 1997 | 1669 | 0.020 |
Why?
|
Financing, Organized | 1 | 2012 | 203 | 0.020 |
Why?
|
Microbial Viability | 1 | 2012 | 237 | 0.020 |
Why?
|
Toll-Like Receptor 2 | 1 | 2013 | 348 | 0.020 |
Why?
|
Fluorescein | 1 | 2011 | 175 | 0.020 |
Why?
|
Medical Records | 1 | 1996 | 1411 | 0.020 |
Why?
|
Students, Medical | 1 | 2004 | 1964 | 0.020 |
Why?
|
Surface Plasmon Resonance | 1 | 2011 | 272 | 0.020 |
Why?
|
HeLa Cells | 1 | 2017 | 3076 | 0.020 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 2276 | 0.020 |
Why?
|
Microbial Sensitivity Tests | 1 | 1997 | 1967 | 0.020 |
Why?
|
Specimen Handling | 1 | 2015 | 708 | 0.020 |
Why?
|
Urban Health | 2 | 1995 | 535 | 0.020 |
Why?
|
Curriculum | 1 | 2004 | 3782 | 0.020 |
Why?
|
Mandatory Programs | 1 | 1991 | 86 | 0.020 |
Why?
|
Membrane Glycoproteins | 1 | 2021 | 3713 | 0.020 |
Why?
|
Tanzania | 1 | 2014 | 1407 | 0.020 |
Why?
|
Genetic Variation | 2 | 2015 | 6611 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2017 | 2204 | 0.020 |
Why?
|
Interferon Type I | 1 | 2014 | 569 | 0.020 |
Why?
|
Platelet Count | 1 | 2012 | 787 | 0.020 |
Why?
|
Hospitals | 1 | 2023 | 3904 | 0.020 |
Why?
|
Private Sector | 1 | 2012 | 396 | 0.020 |
Why?
|
Immunomagnetic Separation | 1 | 2009 | 79 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2013 | 1609 | 0.020 |
Why?
|
Interviews as Topic | 2 | 2014 | 2744 | 0.020 |
Why?
|
Adsorption | 1 | 2009 | 198 | 0.020 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2012 | 1683 | 0.020 |
Why?
|
Botswana | 1 | 2012 | 1065 | 0.020 |
Why?
|
Principal Component Analysis | 1 | 2012 | 948 | 0.020 |
Why?
|
Attitude to Health | 1 | 1998 | 2025 | 0.020 |
Why?
|
Gene Knockout Techniques | 1 | 2012 | 808 | 0.020 |
Why?
|
Molecular Epidemiology | 1 | 2011 | 473 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2015 | 15471 | 0.020 |
Why?
|
Hepatitis B Antigens | 1 | 1988 | 38 | 0.020 |
Why?
|
Consensus | 1 | 2018 | 3214 | 0.020 |
Why?
|
Pediatrics | 2 | 2016 | 3628 | 0.020 |
Why?
|
Mothers | 2 | 2004 | 2209 | 0.020 |
Why?
|
Diffusion of Innovation | 1 | 2012 | 732 | 0.020 |
Why?
|
Virion | 1 | 2010 | 430 | 0.020 |
Why?
|
ROC Curve | 1 | 2015 | 3629 | 0.020 |
Why?
|
Culicidae | 1 | 1988 | 111 | 0.020 |
Why?
|
Piperazines | 1 | 2018 | 2553 | 0.020 |
Why?
|
Community Health Services | 1 | 1992 | 659 | 0.020 |
Why?
|
Neutrophils | 1 | 2020 | 3785 | 0.020 |
Why?
|
Bacterial Infections | 1 | 2015 | 1397 | 0.020 |
Why?
|
Up-Regulation | 1 | 2016 | 4148 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2017 | 6512 | 0.020 |
Why?
|
Proteome | 1 | 2017 | 1891 | 0.020 |
Why?
|
Culex | 1 | 1986 | 18 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2011 | 2749 | 0.020 |
Why?
|
Sex Distribution | 1 | 2012 | 2280 | 0.020 |
Why?
|
Intestinal Mucosa | 1 | 2018 | 3044 | 0.020 |
Why?
|
Sequence Analysis, Protein | 1 | 2007 | 265 | 0.020 |
Why?
|
Chimera | 1 | 2007 | 454 | 0.020 |
Why?
|
Family Health | 1 | 1991 | 1255 | 0.020 |
Why?
|
Patient Participation | 1 | 2015 | 1448 | 0.020 |
Why?
|
Hepacivirus | 1 | 1993 | 1344 | 0.020 |
Why?
|
Program Development | 1 | 2012 | 1300 | 0.020 |
Why?
|
Interleukin-2 | 1 | 2012 | 1895 | 0.020 |
Why?
|
Lipopolysaccharides | 1 | 2013 | 2222 | 0.020 |
Why?
|
Mycobacterium tuberculosis | 1 | 1996 | 1930 | 0.020 |
Why?
|
Occupational Diseases | 1 | 1993 | 1458 | 0.020 |
Why?
|
Binding Sites | 1 | 2014 | 6023 | 0.020 |
Why?
|
Health Services Research | 1 | 2012 | 1818 | 0.020 |
Why?
|
Cell Lineage | 1 | 2014 | 2576 | 0.010 |
Why?
|
Point Mutation | 1 | 2010 | 1596 | 0.010 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2014 | 1902 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2015 | 3450 | 0.010 |
Why?
|
Cicatrix | 1 | 1989 | 799 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2015 | 3709 | 0.010 |
Why?
|
Self Report | 1 | 2014 | 3773 | 0.010 |
Why?
|
Academic Medical Centers | 1 | 1993 | 2784 | 0.010 |
Why?
|
Length of Stay | 1 | 1996 | 6526 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 2 | 2016 | 18068 | 0.010 |
Why?
|
Hemoglobins | 1 | 2008 | 1531 | 0.010 |
Why?
|
Contraception Behavior | 1 | 2003 | 187 | 0.010 |
Why?
|
Survival Analysis | 1 | 2014 | 10115 | 0.010 |
Why?
|
Proteomics | 1 | 2015 | 3914 | 0.010 |
Why?
|
Maternal Age | 1 | 2003 | 805 | 0.010 |
Why?
|
Epidemiologic Research Design | 1 | 2003 | 368 | 0.010 |
Why?
|
Base Sequence | 1 | 2011 | 12430 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2017 | 17173 | 0.010 |
Why?
|
Aged | 3 | 2024 | 171786 | 0.010 |
Why?
|
Wounds and Injuries | 1 | 2012 | 2517 | 0.010 |
Why?
|
Apoptosis | 1 | 2016 | 9527 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2011 | 3580 | 0.010 |
Why?
|
Infant Mortality | 1 | 2004 | 754 | 0.010 |
Why?
|
Peptides | 1 | 2011 | 4353 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 1997 | 5375 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2015 | 9549 | 0.010 |
Why?
|
Safety | 1 | 2003 | 1161 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 1992 | 3928 | 0.010 |
Why?
|
Voluntary Programs | 1 | 1998 | 48 | 0.010 |
Why?
|
Population Control | 1 | 1997 | 23 | 0.010 |
Why?
|
Healthcare Disparities | 1 | 2012 | 3421 | 0.010 |
Why?
|
Fees, Medical | 1 | 1997 | 111 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2012 | 10486 | 0.010 |
Why?
|
Ethics Committees, Research | 1 | 1998 | 196 | 0.010 |
Why?
|
Aging | 1 | 2015 | 8745 | 0.010 |
Why?
|
Algorithms | 1 | 2017 | 14201 | 0.010 |
Why?
|
Social Problems | 1 | 1995 | 108 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2010 | 12806 | 0.010 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 1997 | 348 | 0.010 |
Why?
|
Cross-Over Studies | 1 | 1999 | 2108 | 0.010 |
Why?
|
Ethics Committees | 1 | 1992 | 51 | 0.010 |
Why?
|
Mental Disorders | 1 | 2012 | 6876 | 0.010 |
Why?
|
Ulcer | 1 | 1993 | 203 | 0.010 |
Why?
|
Population Dynamics | 1 | 1992 | 314 | 0.010 |
Why?
|
Schools, Medical | 1 | 1997 | 883 | 0.010 |
Why?
|
Forecasting | 1 | 1997 | 2945 | 0.000 |
Why?
|
Education, Medical, Undergraduate | 1 | 1997 | 1085 | 0.000 |
Why?
|
Health Care Reform | 1 | 1997 | 1262 | 0.000 |
Why?
|
Aged, 80 and over | 1 | 1989 | 59739 | 0.000 |
Why?
|
Malaria | 1 | 1992 | 1249 | 0.000 |
Why?
|
Internship and Residency | 1 | 1997 | 5956 | 0.000 |
Why?
|